1. Home
  2. MDGL vs TFX Comparison

MDGL vs TFX Comparison

Compare MDGL & TFX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MDGL
  • TFX
  • Stock Information
  • Founded
  • MDGL 2011
  • TFX 1943
  • Country
  • MDGL United States
  • TFX United States
  • Employees
  • MDGL N/A
  • TFX N/A
  • Industry
  • MDGL Biotechnology: Pharmaceutical Preparations
  • TFX Medical/Dental Instruments
  • Sector
  • MDGL Health Care
  • TFX Health Care
  • Exchange
  • MDGL Nasdaq
  • TFX Nasdaq
  • Market Cap
  • MDGL 6.1B
  • TFX 5.3B
  • IPO Year
  • MDGL N/A
  • TFX N/A
  • Fundamental
  • Price
  • MDGL $314.31
  • TFX $116.88
  • Analyst Decision
  • MDGL Strong Buy
  • TFX Hold
  • Analyst Count
  • MDGL 9
  • TFX 10
  • Target Price
  • MDGL $420.63
  • TFX $176.50
  • AVG Volume (30 Days)
  • MDGL 282.4K
  • TFX 522.9K
  • Earning Date
  • MDGL 08-06-2025
  • TFX 07-31-2025
  • Dividend Yield
  • MDGL N/A
  • TFX 1.17%
  • EPS Growth
  • MDGL N/A
  • TFX N/A
  • EPS
  • MDGL N/A
  • TFX 3.20
  • Revenue
  • MDGL $317,383,000.00
  • TFX $3,010,144,000.00
  • Revenue This Year
  • MDGL $286.17
  • TFX $2.98
  • Revenue Next Year
  • MDGL $64.17
  • TFX $4.72
  • P/E Ratio
  • MDGL N/A
  • TFX $36.39
  • Revenue Growth
  • MDGL N/A
  • TFX 0.29
  • 52 Week Low
  • MDGL $200.63
  • TFX $115.94
  • 52 Week High
  • MDGL $377.46
  • TFX $249.91
  • Technical
  • Relative Strength Index (RSI)
  • MDGL 64.53
  • TFX 41.62
  • Support Level
  • MDGL $284.02
  • TFX $116.32
  • Resistance Level
  • MDGL $311.21
  • TFX $121.75
  • Average True Range (ATR)
  • MDGL 11.94
  • TFX 2.88
  • MACD
  • MDGL 2.74
  • TFX 0.10
  • Stochastic Oscillator
  • MDGL 100.00
  • TFX 11.71

About MDGL Madrigal Pharmaceuticals Inc.

Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.

About TFX Teleflex Incorporated

Teleflex is a Wayne, Pennsylvania-based manufacturer of hospital supplies and medical devices primarily in the bloodstream/vascular and surgical areas. The firm reports results across seven segments: vascular access (24% of 2024 sales), interventional (19%), anesthesia (13%), surgical (15%), interventional urology (11%), original-equipment manufacturing (11%), and other (7%). Geographic exposure for the business is primarily in the US, which accounts for 60% of revenue, with international markets making up the remainder.

Share on Social Networks: